Effect of the Dysbindin Gene on Antimanic Agents in Patients with Bipolar I Disorder

• 발행기관: 대한신경정신의학회
• 저자명: DongHwan Yun ChiUn Pae Antonio Drago Laura Mandelli Diana De Ronchi Ashwin A. Patkar InHo Paik Aless
• 간행물 정보: 『Psychiatry Investigation』제5권 제2호, 102~105쪽, 전체 4쪽
• 주제분류: 의약학 > 정신과학
• 파일형태: PDF
• 발행일자: 2008.06.30

영문 초록

Objective-We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment. Methods-A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (±19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T, rs2005976 G/A, rs760761 C/T and rs2619522 A/C). Results-There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors. Conclusion-Although the small number of subjects is an important limitation in our study, DTNBP1 does not seem to be involved in acute antimanic efficacy.

목차

INTRODUCTION

METHODS

RESULTS

DISCUSSION

ACKNOWLEDGEMENTS

REFERENCES

키워드

Pharmacogenetics Dysbindin Bipolar disorder Antimanic agents